Abstract. The aim of the present study was to investigate the resistance of plasmid-mediated AmpC β-lactamase in Pseudomonas aeruginosa, to detect and identify the AmpC genotype and to provide evidence for antibiotic applications in the clinic. Resistance phenotype in 108 strains of clinically isolated P. aeruginosa was determined by Kirby-Bauer disk test and cefoxitin three dimensional test in AmpC-positive strains. Plasmids were extracted from AmpC-positive strains using the SDS-alkali splitting technique. The depurated plasmid was used to amplify AmpC β-lactamase genes by PCR. Positive PCR products were sequenced by the Shanghai Sangon Biological Engineering Technology Company. Gene homology of PCR products with other index sample gene sequences was compared. In the present study, 28 AmpC enzyme-positive P. aeruginosa strains among 108 were identified. Multidrug-resistance to antibiotics was observed in positive AmpC P. aeruginosa strains and a new P. aeruginosa strain of plasmid-mediated CMY-7 type AmpC enzyme was identified. In addition, AmpC type β-lactamases were revealed to be important in the resistance mechanism to antibiotics in P. aeruginosa. This is the first report of CMY-7 plasmid-mediated AmpC enzyme expression in P. aeruginosa.
Introduction
The increasing use and application of broad-spectrum antibiotics has led to increased reports of bacterial drug resistance and clinical infection. At present, drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, vancomycinresistant Enterococcus, multidrug-resistant Baumanii, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa are increasingly being detected in clinical and laboratory settings (1) . Appearance of pan-resistant bacteria, including Cray Borrelia, which produces New Delhi Metallo β-lactamase-1, an enzyme responsible for generating resistance (2) , is causing an even greater challenge to humans. Therefore, study of clinical bacterial drug resistance and mechanisms and the development of solutions to bacterial resistance is important. Previously, Gram-negative bacilli AmpC β-lactamase was understood to be generated by chromosome mediation only. However, Papanicolaou et al (3) identified plasmid-mediated AmpC β-lactamase (MIR-1) in a strain of Cray Borrelia bacterium isolated from a patient in Rhode Island Hospital (USA) in 1989. Following this, the plasmid-mediated AmpC enzyme was rapidly identified in a number of other countries. At present, more than 20 plasmid-mediated AmpC enzymes have been identified. The plasmid-mediated AmpC enzyme is resistant to antibiotics, enabling the plasmid to continue to express the protein at high levels and carry multiple drug-resistant genes. Plasmid-mediated drug resistance is transmitted between members of the same or different bacterial species. Transmission is rapid and performed at a range of distances. Therefore, understanding of the mechanism and elucidation of solutions to plasmid-mediated AmpC enzyme resistance is crucial.
P. aeruginosa is one of the main bacterial strains associated with hospital infections, including burns, cystic pulmonary fibrosis and ventilator-associated infections. In addition, P. aeruginosa is resistant to multiple antibiotics and is associated with high rates of mortality (4) (5) (6) . A number of drug resistance mechanisms have been identified in P. aeruginosa, including production of β-lactamase (extended-spectrum β-lactamases or AmpC) (7), alteration of penicillin-binding protein expression (8) , formation of biomembranes, expression of cytomembrane permeability barriers (9, 10) or active multidrug efflux pumps, including mex-ABoprM (11) and alterations in channel protein expression, including oprD (11, 12) . At present, P. aeruginosa plasmid-mediated AmpC β-lactamase has not been studied. The present study aimed to investigate plasmid-mediated AmpC in clinically-isolated P. aeruginosa through identification of the genetype of a drug-resistant strain, to aid clinical antibiotic applications. Primary screening test of specimens. Isolated P. aeruginosa was inoculated onto a blood plate and cultured at 37˚C overnight. The following day, cultures were suspended in 0.9% stroke-physiological saline solution (Maxwell turbidity, 0.5) and coated uniformly onto M-H plates with sterile cotton swabs. Cefoxitin (FOX), ceftazidime (CAZ), cefotaxime/clavulanic acid (CTX/CA) and imipenem (IMP) drug-sensitive slips were symmetrically placed onto the M-H plates with bacterial suspension using sterile forceps and cultured overnight at 37˚C. The next day, bacteriostatic rings of drug-sensitive slips were observed and the diameters of bacteriostatic rings were measured with a vernier caliper. According to criteria prepared by the National Clinical Laboratory Standardization Committee of America (13), bacteriostatic ring diameters of ≤18, ≤21, ≤22 and ≥13 mm for FOX, CTX/CA, CAZ and IMP, respectively, were indicative of strains expressing the AmpC enzyme.
Study on drug resistance of
Preparation of AmpC enzyme. P. aeruginosa stains identified by screening to express the AmpC enzyme were inoculated into 10 ml LB broth and cultured overnight in a thermostat shaker at a speed of 80-100 rpm at 37˚C. Subsequently, the culture mixture was centrifuged in a refrigerated centrifuge at 4˚C to remove the supernatant. Bacterial pellets were frozen for 30 min at -80˚C and then thawed in a water bath. The freezethaw cycle was performed 5 times. Following this, bacteria were suspended in 1.5 ml PBS buffer (0.01 M) in an EP tube, mixed uniformly by agitation and centrifuged at low temperature to obtain the supernatant. The supernatant contained the AmpC enzyme and was filtered using a 0.22-µm microporous membrane. Next, the filtrate was inoculated onto the blood plate and cultured overnight at 37˚C. Bacterial growth was observed and negative filtrates were stored at -20˚C. (Fig. 1) .
PCR amplification. Purified plasmid DNA was used for PCR amplification templates. For each DNA template, 6 reactions were performed. An amplification product was obtained using one pair of primers of a total of 6 primer pairs. This primer was of CIT type and the target length was 251 bp (Fig. 2) . Within 22 strains of plasmid-positive P. aeruginosa, a single purified PCR amplification product was positive for this band.
Sequencing analysis. The positive strain revealing a target band of 251 bp was sequenced. The sequencing results are shown in Fig. 3 .
Homology comparison. The sequenced product (2-220 bp) was identified to exhibit 99.5% (218/219) homology to the A. cloacae K9973 β-lactamase AmpC gene (881-1099 bp) The total length of the β-lactamase AmpC gene sequence in A. cloacae is 1165 bp (Fig. 4) .
Discussion
P. aeruginosa is one of the main bacterial species responsible for severe hospital infections (14) and is resistant to a number of antibacterial drugs. P. aeruginosa has several drug-resistant mechanisms: 1) the generatation of β-lactamase enzymes; 2) efflux pumps (e.g. mex2oprM); 3) target-site or outer membrane modifications. Multiple drug resistance is usually the result of the chromosomal and plasmid-encoded AmpC enzymes (15) (16) (17) . Drug resistance cannot currently be detected by routine antibiotic sensitivity tests and the detection of the process is complex (18) . At present, no universal test exists for the detection of AmpC β-lactamase; however, the three-dimensional test was previously reported to be the most suitable detection method available (19) . In the present study, 108 strains of P. aeruginosa were screened using K-B drug-sensitive slips. An AmpC enzyme-positive result was observed in 30 strains and the three-dimensional test of FOX was performed, identifying 28 strains as AmpC enzyme-positive. The detection coincidence rate of the two methods for AmpC enzyme-positive stains was 93.3%.
The three-dimensional test identified 28 AmpC enzyme-positive strains of P. aeruginosa. Following this, electrophoresis of plasmid extracts identified representative plasmid bands in 22 strains. Six strains were negative and had lost or did not carry plasmids initially. PCR amplification analysis identified positive plasmid-mediated AmpC enzyme expression in a single strain, demonstrating that the plasmid-mediated AmpC enzyme was present in P. aeruginosa; however, the proportion of plasmid-positive strains carrying the AmpC enzyme gene was low. It is possible that the P. aeruginosa strains that the three-dimensional test showed as positive could produce the majority of the chromosomal-mediated AmpC enzyme.
Previous studies on plasmid-mediated AmpC β-lactamase are largely restricted to the bacterila strains A. cloacae and Cray Borrelia (20) (21) (22) . A limited number of studies have analyzed drug resistance in P. aeruginosa plasmid-mediated AmpC β-lactamase. In 2003, Shahid et al (23) isolated P. aeruginosa strains exhibiting plasmid-mediated AmpC enzyme from burns patients in an intensive care hospital in Northern India. In the domestic environment, a single strain of E. coli was previously observed to exhibit ACT-1 plasmid AmpC enzyme. However, no domestic reports on P. aeruginosa plasmid-mediated AmpC enzyme expression currently exist. The present study identified a single strain of P. aeruginosa plasmid-mediated AmpC enzyme expression using plasmid extraction, PCR amplification, product sequencing and BLAST homology comparison. A 99.5% homology with the A. cloacae K9973-β-lactamase AmpC gene sequence was identified. The overall length of A. cloacae K9973-β-lactamase AmpC gene sequence was 1,165 bp, consistent with the gene sequence of A. cloacae K9973-generating CMY-7 AmpC enzyme previously identified by Lee et al (24) . The present study is the first reported identification of plasmid-mediated AmpC β-lactamase expression in P. aeruginosa.
